Recovery and measurable improvement timescales in muscular dystrophy extend from weeks to months rather than days. Initial local inflammatory responses to infusion subside over 2–4 weeks. Functional assessment typically occurs at 3, 6, and 12 months post-infusion to detect any stabilisation of strength or slowing of decline. Meaningful outcomes — such as maintained ambulation or reduced wheelchair dependence — require patience and realistic expectations. Many patients experience no obvious recovery period because primary goal is halting decline, not restoring lost function. Full safety monitoring and adverse-event surveillance continue for 12–24 months post-treatment.
Clinical trials in muscular dystrophy have predominantly featured small cohorts and observational designs. Four recruiting studies suggest ongoing clinical investigation, though definitive efficacy data remain limited. Some trials reported modest improvements in muscle strength measures and reduced serum creatine kinase levels following MSC infusion, whilst others showed minimal functional benefit. The heterogeneity of dystrophy subtypes means outcomes differ markedly between Duchenne, Becker, and limb-girdle forms. Current evidence supports MSCs as a potential supportive therapy rather than curative, with strongest signals emerging from early-intervention cohorts. Long-term safety data are sparse, and disease progression often continues despite treatment.
Am I a candidate? → · Muscular Dystrophy: full overview → · Muscular Dystrophy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估